Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PRISM: A Double Blind, Randomized, Vehicle Controlled Phase 2 Study to Assess the Safety and Efficacy of BPX-04 Minocycline Topical Gel in the Treatment of Inflammatory Lesions of Papulopustular Rosacea

Next Previous
Trial Profile

PRISM: A Double Blind, Randomized, Vehicle Controlled Phase 2 Study to Assess the Safety and Efficacy of BPX-04 Minocycline Topical Gel in the Treatment of Inflammatory Lesions of Papulopustular Rosacea

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Minocycline (Primary)
  • Indications Rosacea
  • Focus Therapeutic Use
  • Acronyms PRISM
  • Sponsors BioPharmX Corporation; Trex Wind-down

    • Most Recent Events

    • 15 Feb 2024 According to Timber Pharmaceuticals media release, Timber Pharmaceuticals has changed its name to Trex Wind-down
    • 25 Jun 2019 According to a BioPharmX media release, the secondary endpoint, the proportion of subjects with a two-grade improvement to clear or almost clear on the IGA scale from baseline to week 12 from this study was included to collect sufficient data to design a Phase III study with co-primary efficacy endpoints.
    • 25 Jun 2019 According to a BioPharmX Corporation media release, Dr. Mark Amster is an investigator in the clinical trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top